title: Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia.
abstract: Several reports have demonstrated the persistent detection of AML1-MTG8 fusion products, representing minimal residual disease (MRD), in patients with t(8;21) acute myelogenous leukaemia (AML) who are in long-term remission. It is probable that immune-mediated mechanisms that are able to suppress the expansion of MRD may result in the continuance of remission. It was previously shown that some t(8;21) AML patients had high anti-MTG8 antibody titres. MTG8 expression in normal adult tissues is limited to the brain or heart in which human leucocyte antigen (HLA) class I cell-surface antigens are either not or are only faintly detectable. We hypothesized that the overexpression of the MTG8 gene in t(8;21) AML cells could act as a possible tumour antigen, which might be able to induce the immune-mediated suppression of the expansion of MRD. We were able to induce HLA-A0201-restricted cytotoxic T-lymphocyte (CTL) lines against an MTG8 peptide (MTG8b amino acids 182-191) using monocyte-derived dendritic cells from a healthy donor. T-cell receptor (TCR)Valpha17, TCRVbeta14 and 15, and TCRJbeta2.1 and 2.3 are predominantly used in these CTL lines. Our data, which suggest that the MTG8 protein could be one of the tumour antigens recognized by CTLs, may be helpful in further investigations of TCR analysis in t(8;21) AML patients with HLA-A0201 who are in long-term remission.
authors: The Cancer Centre, Kyushu University Hospital, The First Department of Internal Medicine, Fukuoka University, Fukuoka, Japan. mmaeda@aicompro.com
authors: M
authors: M
authors: Maeda
authors: T
authors: T
authors: Otsuka
authors: N
authors: N
authors: Kimura
authors: T
authors: T
authors: Kozu
authors: T
authors: T
authors: Fukuyama
authors: N
authors: N
authors: Uchida
authors: Y
authors: Y
authors: Sugio
authors: Y
authors: Y
authors: Itoh
authors: T
authors: T
authors: Iino
authors: S
authors: S
authors: Inaba
authors: Y
authors: Y
authors: Niho
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050676:Core Binding Factor Alpha 2 Subunit; D003601:Cytotoxicity Tests, Immunologic; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000235:genetics / Q000276:immunology*; D000939:Epitopes; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology*; D008213:Lymphocyte Activation; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000276:immunology*; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014157:Transcription Factors / Q000235:genetics / Q000276:immunology*; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D050676:Core Binding Factor Alpha 2 Subunit; D017931:DNA Primers; D004268:DNA-Binding Proteins; D000939:Epitopes; D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; C493728:RUNX1 protein, human; C082222:RUNX1T1 protein, human; D014157:Transcription Factors